Metsera (MTSR) Competitors $25.87 +0.09 (+0.35%) As of 10:03 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsTrends MTSR vs. SRPT, PCVX, ASND, QGEN, ROIV, RVMD, LNTH, LEGN, TLX, and BBIOShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Sarepta Therapeutics Vaxcyte Ascendis Pharma A/S Qiagen Roivant Sciences Revolution Medicines Lantheus Legend Biotech Telix Pharmaceuticals Limited American Depositary Shares BridgeBio Pharma Sarepta Therapeutics (NASDAQ:SRPT) and Metsera (NASDAQ:MTSR) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking. Do analysts rate SRPT or MTSR? Sarepta Therapeutics presently has a consensus price target of $170.41, indicating a potential upside of 70.80%. Metsera has a consensus price target of $47.00, indicating a potential upside of 82.31%. Given Metsera's stronger consensus rating and higher possible upside, analysts plainly believe Metsera is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 1 Sell rating(s) 3 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor SRPT or MTSR? Sarepta Therapeutics received 1462 more outperform votes than Metsera when rated by MarketBeat users. However, 100.00% of users gave Metsera an outperform vote while only 75.18% of users gave Sarepta Therapeutics an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes146675.18% Underperform Votes48424.82% MetseraOutperform Votes4100.00% Underperform VotesNo Votes Is SRPT or MTSR more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Metsera's net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat Metsera's return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Metsera N/A N/A N/A Do institutionals & insiders have more ownership in SRPT or MTSR? 86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer SRPT or MTSR? In the previous week, Sarepta Therapeutics had 6 more articles in the media than Metsera. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 7 mentions for Metsera. Sarepta Therapeutics' average media sentiment score of 0.65 beat Metsera's score of 0.59 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Metsera 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, SRPT or MTSR? Metsera has lower revenue, but higher earnings than Sarepta Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.90B5.09-$535.98M$2.2843.76MetseraN/AN/AN/AN/AN/A SummarySarepta Therapeutics beats Metsera on 11 of the 14 factors compared between the two stocks. Remove Ads Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.66B$6.94B$5.64B$8.08BDividend YieldN/A2.72%4.89%4.04%P/E RatioN/A6.1223.7319.00Price / SalesN/A226.08381.75120.61Price / CashN/A65.6738.0534.64Price / BookN/A6.656.904.26Net IncomeN/A$139.34M$3.18B$247.00M7 Day Performance-2.42%-0.67%6.23%-2.60%1 Month Performance-18.55%-5.95%1.18%-8.62%1 Year PerformanceN/A-5.21%12.45%2.07% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$25.87+0.3%$47.00+81.7%N/A$2.67BN/A0.0081Quiet Period ExpirationSRPTSarepta Therapeutics4.633 of 5 stars$103.03-2.4%$170.41+65.4%-18.2%$10.24B$1.90B82.421,314PCVXVaxcyte2.3685 of 5 stars$71.18-4.9%$147.50+107.2%+2.3%$9.17BN/A-15.47160Analyst ForecastPositive NewsASNDAscendis Pharma A/S3.0274 of 5 stars$145.74-3.8%$202.36+38.8%-2.3%$8.84B$363.64M-20.531,017Positive NewsQGENQiagen3.9481 of 5 stars$39.76-0.3%$47.71+20.0%-9.3%$8.82B$1.98B110.705,967Short Interest ↓ROIVRoivant Sciences1.9741 of 5 stars$10.64+0.4%$18.08+70.0%+3.0%$7.59B$122.59M-70.93860RVMDRevolution Medicines4.2083 of 5 stars$39.210.0%$66.31+69.1%+16.8%$7.29B$742,000.00-10.92250LNTHLantheus4.6879 of 5 stars$106.34+6.1%$132.86+24.9%+65.7%$7.28B$1.53B17.69700Short Interest ↓LEGNLegend Biotech2.0293 of 5 stars$35.26+3.2%$79.50+125.5%-41.3%$6.44B$520.18M-37.121,800Earnings ReportAnalyst ForecastNews CoverageTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.40+1.1%$22.00+19.6%N/A$6.20B$783.21M0.00N/AAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeBBIOBridgeBio Pharma4.4915 of 5 stars$31.57-2.0%$51.55+63.3%+13.6%$6.00B$221.90M-11.08400 Remove Ads Related Companies and Tools Related Companies SRPT Alternatives PCVX Alternatives ASND Alternatives QGEN Alternatives ROIV Alternatives RVMD Alternatives LNTH Alternatives LEGN Alternatives TLX Alternatives BBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
